Physician profile
Jean F Smith
NPI 1043241615
$3,335.51
in general payments reported to CMS, 2019-2025
35 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,076 · 2020: $204 · 2021: $288 · 2022: $490 · 2023: $629 · 2024: $466 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,277.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $408.92 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $397.32 | 2019-2023 | |
| Inspire Medical Systems, INC. | $343.32 | 2024-2025 | Inspire |
| Nestle Healthcare Nutrition INC. | $338.75 | 2021-2023 | |
| Lilly USA, LLC | $219.99 | 2019-2024 | Jardiance, Amyvid |
| Astrazeneca Pharmaceuticals LP | $181.19 | 2019-2024 | Breztri, Farxiga |
| Abbvie INC. | $172.41 | 2021-2024 | Ubrelvy |
| Amgen INC. | $139.85 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $122.15 | 2019 | |
| Merck Sharp & Dohme LLC | $114.08 | 2019-2023 | Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $110.68 | 2022-2023 | |
| Avanir Pharmaceuticals, INC. | $83.34 | 2019 | |
| Eisai INC. | $73.30 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.23 | 2019 | |
| Janssen Pharmaceuticals, INC | $51.20 | 2019-2023 | Xarelto |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $46.65 | 2024 | Nuzyra |
| Upsher-Smith Laboratories LLC | $43.30 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $39.13 | 2019-2020 | |
| Melinta Therapeutics, LLC | $35.03 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $33.26 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $31.28 | 2019 | |
| Vanda Pharmaceuticals INC. | $28.88 | 2023 | Hetlioz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.11 | 2019 | |
| Lundbeck LLC | $25.96 | 2024 | Rexulti |
| Exact Sciences Corporation | $24.67 | 2023 | Cologuard Collection Kit |
| Antares Pharma, INC. | $22.29 | 2019 | |
| Abbott Laboratories | $21.46 | 2025 | Freestyle Libre 3 |
| Indivior INC. | $20.76 | 2024 | Sublocade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.26 | 2023 | Trulance, Xifaxan |
| Shire North American Group INC | $17.27 | 2019 | |
| Medtronic Minimed, INC. | $16.27 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.79 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.64 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.49 | 2022 | |
| Daiichi Sankyo INC. | $13.28 | 2023 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.